Wellington Biomedical Innovation Master Investors (Cayman) II L.P. - Sep 16, 2024 Form 4 Insider Report for MBX Biosciences, Inc. (MBX)

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) II L.P., By: Wellington Management Company LLP, as Investment Adviser, /s/ Jennifer C. Boylan, Authorized Person
Stock symbol
MBX
Transactions as of
Sep 16, 2024
Transactions value $
$0
Form type
4
Date filed
9/17/2024, 07:15 PM
Previous filing
Sep 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBX Common Stock Conversion of derivative security +1.39M 1.39M Sep 16, 2024 Direct F1
transaction MBX Common Stock Conversion of derivative security +404K +29.13% 1.79M Sep 16, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBX Series B Preferred Stock Conversion of derivative security $0 -16.7M -100% $0.00 0 Sep 16, 2024 Common Stock 1.39M Direct F1
transaction MBX Series C Preferred Stock Conversion of derivative security $0 -4.85M -100% $0.00 0 Sep 16, 2024 Common Stock 404K Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Wellington Biomedical Innovation Master Investors (Cayman) II L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Immediately prior to the closing of the Issuer's initial public offering, each share of Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series B Preferred Stock had no expiration date.
F2 Immediately prior to the closing of the Issuer's initial public offering, each share of Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 12.0221-for-one basis. The Series C Preferred Stock had no expiration date.